论文部分内容阅读
目的探讨奥氮平在首发精神分裂症的儿童青少年患者中的治疗效果和安全性。方法选取儿童青少年首发精神分裂症的患者80例,随机地分为研究组(n=40)和对照组(n=40),对研究组的患者给予奥氮平进行治疗,对照组的患者给予利培酮进行治疗。比较两组患者的治疗有效率。采用阳性和阴性症状量表和副反应量表对两组患者在治疗前和治疗后的第1、2、6、8周进行评定,并且比较两组的评定结果。结果两组的治疗总有效率差异无统计学意义(P>0.05),在治疗后的第1、2周,研究组患者的PANSS评分总分显著低于对照组(P<0.05),对照组患者的静坐不能和震颤的不良反应发生率显著高于研究组(P<0.05),其余不良反应两组之间差异无统计学意义,研究组患者的体重增加值显著高于对照组(P<0.05)。结论奥氮平是一种起效快、疗效显著的治疗儿童青少年精神分裂症的药物,具有较好的安全性,但是奥氮平能够增加患者的体重,对于应用于儿童青少年精神分裂症患者需要慎重考虑。
Objective To investigate the therapeutic effect and safety of olanzapine in children and adolescents with first-episode schizophrenia. Methods Eighty children with first-episode schizophrenia in children and adolescents were randomly divided into study group (n = 40) and control group (n = 40). Patients in study group were treated with olanzapine and patients in control group were given Risperidone for treatment. Therapeutic efficiency was compared between the two groups. The positive and negative symptom scales and the side-response scale were used to evaluate the two groups before treatment and at the 1st, 2nd, 6th and 8th week after treatment, and the results of the two groups were compared. Results There was no significant difference in total effective rate between the two groups (P> 0.05). In the first and second week after treatment, the PANSS score of the study group was significantly lower than that of the control group (P <0.05) The incidence of adverse reactions to meditation and tremor was significantly higher in the study group than in the study group (P <0.05). There was no significant difference in the other adverse reactions between the two groups. The weight gain in the study group was significantly higher than that in the control group (P < 0.05). Conclusion Olanzapine is a fast onset and effective treatment of schizophrenia in children and adolescents with good safety, but olanzapine can increase the patient’s weight, for children and adolescents with schizophrenia need consider carefully.